Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?
- Sabrina Valeria Porta,
- ,
- Ignacio Garciá-De La Torre,
- Eloísa Bonfá,
- José A. Gómez-Puerta,
- Laurent Arnaud
- J. M. Ramos Mejía Hospital,
- ,
- Universidad de Guadalajara,
- University of São Paulo,
- Hospital Clinic Barcelona,
- Hôpitaux Universitaires de Strasbourg
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages E651-E658Journal (Volume, Issue Number)
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (Volume 28, Issue 2)Publication milestones
- Published - 01/03/2022
Publication status
ISSN
1076-1608Publication IDs
- Scopus: 85125016501
- PubMed: 34897194
Abstract
Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.